GoAI
Get started
Retractable Technologies, Inc. logo

Retractable Technologies, Inc.

RVP

AMEXHealthcareMedical - Instruments & Supplies

Open in GoAI

Latest quote

$0.7239

$0.00 · 0.00%

Aug 21, 3:55 PM ET

RVP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

61

Undervalued

Momentum

33

Weakening

Sentiment

52

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Retractable Technologies, Inc. is a medical device company focused on the innovation, production, and sale of secure medical instruments, predominantly syringes, for the healthcare sector. Their reach extends across the United States, the broader North and South American continents, and other international territories. The company's diverse product range includes a variety of safety-engineered items such as VanishPoint insulin, tuberculin, and allergy antigen syringes, as well as Patient Safe syringes and Luer Caps. They also offer small diameter tube adapters, blood collection tube holders, allergy trays, and IV safety catheters. Further offerings feature VanishPoint blood collection sets, EasyPoint needles, and VanishPoint autodisable syringes. Distribution of these products occurs through a combination of general and specialized distributors, international partners, and a dedicated direct sales network. Founded in 1994, the company's main operations are headquartered in Little Elm, Texas.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Thomas J. Shaw
Listed since
May 4, 2001
Employees
198

Market position

Volume
7.94K
0.12× average
Average volume
65.15K
Average daily volume
Market cap
21.85M USD
Beta
1.21
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
21.42M USD
P/E (TTM)
-6.06×
P/B (TTM)
0.3×
P/S (TTM)
0.64×
EV / EBITDA
-4.85×
Earnings yield
-54.36%
Free cash flow yield
-32.88%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
1.10%
Operating margin
-66.90%
Net margin
-9.94%
Return on equity
-16.89%
Return on assets
-8.81%
Return on invested capital
-15.16%

Financial health

Debt / equity
0.01×
Current ratio
6.57×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends62%16%-30%-75%Gross margin, FY2021: 50.62%Gross margin, FY2022: 29.80%Gross margin, FY2023: 20.89%Gross margin, FY2024: -3.11%Gross margin, FY2025: 0.12%Operating margin, FY2021: 38.54%Operating margin, FY2022: -0.90%Operating margin, FY2023: -26.35%Operating margin, FY2024: -63.86%Operating margin, FY2025: -52.84%Net margin, FY2021: 29.76%Net margin, FY2022: 5.36%Net margin, FY2023: -16.08%Net margin, FY2024: -35.97%Net margin, FY2025: -32.84%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 50.62%. Gross margin FY2022 29.80%. Gross margin FY2023 20.89%. Gross margin FY2024 -3.11%. Gross margin FY2025 0.12%. Operating margin FY2021 38.54%. Operating margin FY2022 -0.90%. Operating margin FY2023 -26.35%. Operating margin FY2024 -63.86%. Operating margin FY2025 -52.84%. Net margin FY2021 29.76%. Net margin FY2022 5.36%. Net margin FY2023 -16.08%. Net margin FY2024 -35.97%. Net margin FY2025 -32.84%.

Income trends

Revenue

38.27M USD+15.78%

Operating income

−20.22M USD+4.19%

Net income

−12.57M USD-5.71%
Income trends across reported periods209.33M USD125.54M USD41.74M USD−42.05M USDRevenue, FY2021: 188.38M USDRevenue, FY2022: 94.82M USDRevenue, FY2023: 43.6M USDRevenue, FY2024: 33.05M USDRevenue, FY2025: 38.27M USDOperating income, FY2021: 72.6M USDOperating income, FY2022: −852.98K USDOperating income, FY2023: −11.49M USDOperating income, FY2024: −21.11M USDOperating income, FY2025: −20.22M USDNet income, FY2021: 56.06M USDNet income, FY2022: 5.08M USDNet income, FY2023: −7.01M USDNet income, FY2024: −11.89M USDNet income, FY2025: −12.57M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 188.38M USD. Revenue FY2022 94.82M USD. Revenue FY2023 43.6M USD. Revenue FY2024 33.05M USD. Revenue FY2025 38.27M USD. Operating income FY2021 72.6M USD. Operating income FY2022 −852.98K USD. Operating income FY2023 −11.49M USD. Operating income FY2024 −21.11M USD. Operating income FY2025 −20.22M USD. Net income FY2021 56.06M USD. Net income FY2022 5.08M USD. Net income FY2023 −7.01M USD. Net income FY2024 −11.89M USD. Net income FY2025 −12.57M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue38.27M USD33.05M USD43.6M USD94.82M USD188.38M USD
Cost of goods sold38.22M USD34.08M USD34.49M USD66.57M USD93.03M USD
Gross profit47.05K USD−1.03M USD9.11M USD28.25M USD95.35M USD
Research and development675.57K USD673.94K USD581.17K USD525.73K USD901.38K USD
Selling, general, and administrative19.59M USD19.4M USD20.01M USD28.58M USD21.86M USD
Operating expenses20.27M USD20.08M USD20.6M USD29.11M USD22.76M USD
Interest income547.36K USD1M USD1.45M USD9.95K USD266.47K USD
Interest expense87.9K USD122.5K USD152.17K USD170.65K USD227.18K USD
Depreciation and amortization7.77M USD7.57M USD7.53M USD4.6M USD1.26M USD
Operating income−20.22M USD−21.11M USD−11.49M USD−852.98K USD72.6M USD
Net income−12.57M USD−11.89M USD−7.01M USD5.08M USD56.06M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.09

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.170.05-0.06-0.18Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -0.07, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 0.13, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual -0.11, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual -0.12, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 0.01, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual -0.08, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -0.14, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 0.09, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates10.86M9.5M8.13M6.76MQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual 10.35M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 9.07M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual 8.3M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 10.45M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 10.09M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual 9.44M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 7.18M USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 7.2M USD, estimate —, surprise —, Comparison unavailable.

ETFs holding RVP

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
272.14K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
111.93K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research RVP

research.disclaimer